Yahoo! Finance Search - Finance Home - Yahoo! - Help

Friday, March 24 2017 4:11pm ET - U.S. Markets Closed.
Industry Center - Drug Manufacturers - Major
Industry Center > Drug Manufacturers - Major > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
· REIT - Retail
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drug Manufacturers - Major News
Latest News
Sunday, Mar 19, 2017
·Newer type 2 diabetes drugs show heart protective quality in study
Reuters - Sun Mar 19
·AstraZeneca’s CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Hospitalizations for Heart Failure and Death versus Other Type-2 Diabetes Medicines
Business Wire - Sun Mar 19
Saturday, Mar 18, 2017
·J&J and Bayer's Xarelto cuts recurrence of dangerous blood clots in study
Reuters - Sat Mar 18
Friday, Mar 17, 2017
·Fired U.S. Attorney Preet Bharara Was Investigating HHS Chief Tom Price - Report
at TheStreet.com - Fri Mar 17
·$230M deal: AstraZeneca forms COPD drugs collaboration
at bizjournals.com - Fri Mar 17
·Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation
Business Wire - Fri Mar 17
·AstraZeneca Inks $230 Million COPD Drugs Deal
at Investopedia - Fri Mar 17
·How BMY’s Virology Segment Performed in 2016
- Fri Mar 17
·First dedicated outcome trials of empagliflozin in chronic heart failure initiated
PR Newswire - Fri Mar 17
·A Look at Opdivo’s Performance in 2016
- Fri Mar 17
·FDA Rejects AstraZeneca’s Hyperkalemia Drug (AZN, RLYP)
at Investopedia - Fri Mar 17
·AstraZeneca Gets 'Complete Response Letter' From FDA on Hyperkalaemia Treatment
at TheStreet.com - Fri Mar 17
Thursday, Mar 16, 2017
·How Bristol-Myers Squibb’s Oncology Segment Performed in 2016
- Thu Mar 16
·TherapeuticsMD Announces Presentation at the Oppenheimer 27th Annual Healthcare Conference on March 22
Business Wire - Thu Mar 16
·Bristol-Myers Squibb’s Valuation Compared to Its Peers’
- Thu Mar 16
·Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
GlobeNewswire - Thu Mar 16
·Richmond Brothers and Mark Ravich Comment on Rockwell Medical, Inc. Earnings
Business Wire - Thu Mar 16
·That Was Fast: Healthcare ETF Races To New Highs
- Thu Mar 16
·Innovus Pharmaceuticals Announces $3.85 Million Public Offering
Business Wire - Thu Mar 16
·Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
Business Wire - Wed Mar 15
More Latest News...
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Major Headlines
More Finance RSS Feeds


Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2017 Morningstar, Inc. All Rights Reserved. Company information © 2017 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2017, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?